There are 2789 resources available
823TiP - Fluzoparide combined with apatinib mesylate in the treatment of platinum resistant recurrent ovarian cancer: A single arm, single center, prospective clinical study
Presenter: Li xin Sun
Session: ePoster Display
824TiP - An open-label, single arm, phase II trial of niraparib in combination with anti-PD1 antibody in recurrent/advanced stage endometrial cancer patients
Presenter: Jundong Li
Session: ePoster Display
Resources:
Abstract
834P - Role of assessment of IL-6, IL-15 and soluble PD-L1 levels as prognostic and predictive biomarkers in nivolumab-treated relapsed/refractory Hodgkin lymphoma
Presenter: Andrey Chekalov
Session: ePoster Display
835P - Enhancement of the International Prognostic Index with hematologic parameters: A new prognostic model for diffuse large B-cell lymphoma treated with R-CHOP
Presenter: Haizhu Chen
Session: ePoster Display
836P - Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: A Hong Kong population-based study
Presenter: Shing Fung Lee
Session: ePoster Display
777P - A prospective, single-arm, open-label study of camrelizumab, apatinib and nab-paclitaxel in patients with advanced cervical cancer
Presenter: guiling Li
Session: ePoster Display
778P - BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer
Presenter: Giorgio Bogani
Session: ePoster Display
779P - Metronomic low-dose capecitabine in metastatic, recurrent or persistent carcinoma of cervix as 3rd line and beyond
Presenter: Irappa Madabhavi
Session: ePoster Display
841P - IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas
Presenter: Keyu Li
Session: ePoster Display